- Top Workplaces
- Prelude Therapeutics
Prelude Therapeutics
We are a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Our diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Vision
Through purposeful drug discovery, excellence, and rigor, we will build a leading, fully integrated company to deliver novel medicines to patients.
Additional Culture Details
At Prelude, we have created a culture that brings us together through our shared sense of purpose. We are driven to perform and are proud to be a part of an organization that values the collective strength of our diverse and talented employees.
Recent Awards
Company Snapshots
